Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Hofseth BioCare ASA's Debt-to-Equity or its related term are showing as below:
HOFBF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -22.91 Med: 0.97 Max: 273.4
Current: -3.19
During the past 13 years, the highest Debt-to-Equity Ratio of Hofseth BioCare ASA was 273.40. The lowest was -22.91. And the median was 0.97.
HOFBF's Debt-to-Equity is not ranked
in the Consumer Packaged Goods industry.
Industry Median: 0.41
vs HOFBF: -3.19
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Hofseth BioCare ASA Debt-to-Equity Related Terms
Hofseth BioCare ASA Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Hofseth BioCare ASA's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Hofseth BioCare ASA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hofseth BioCare ASA Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Hofseth BioCare ASA's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Hofseth BioCare ASA's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hofseth BioCare ASA (HOFBF) has a Debt-to-Equity of -3.19 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hofseth BioCare ASA and its competitors. According to the industry distribution chart, Hofseth BioCare ASA ranks #999999 out of 1745 companies in the Consumer Packaged Goods industry.
Is Hofseth BioCare ASA's Debt-to-Equity too high?
Hofseth BioCare ASA's current Debt-to-Equity is -3.19. Based on the distribution chart, Hofseth BioCare ASA ranks #999999 out of 1745 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Hofseth BioCare ASA has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Hofseth BioCare ASA's Debt-to-Equity compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Hofseth BioCare ASA ranks #999999 out of 1745 companies for Debt-to-Equity. This places Hofseth BioCare ASA in the lower half of its industry. The industry median Debt-to-Equity is 0.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.41, based on 1,745 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Hofseth BioCare ASA and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hofseth BioCare ASA's current Debt-to-Equity is -3.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hofseth BioCare ASA stock overvalued right now?
Hofseth BioCare ASA (HOFBF) has a current Debt-to-Equity of -3.19. The stock's GF Value™ is $0.26, compared to a current price of $0.17 — trading 35.9% below its estimated fair value. The current Debt-to-Equity is -3.19. Hofseth BioCare ASA's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Hofseth BioCare ASA (HOFBF), the current Debt-to-Equity is -3.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hofseth BioCare ASA (HOFBF) Overvalued in 2026?
Based on GuruFocus' analysis, Hofseth BioCare ASA stock appears to be undervalued.
The current stock price of $0.17 is trading 35.9% below its estimated GF Value™ of $0.26.
Key valuation signals for HOFBF:
Debt-to-Equity: -3.19
GF Value™: $0.26 vs. price of $0.17 (35.9% below fair value)
No single metric tells the full story. See the HOFBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hofseth BioCare ASA is a Norway-based company engaged in the business of developing, manufacturing, marketing, and selling marine ingredients such as oil, calcium, and protein products. Its brands, which also generate revenue, include salmon oil (OmeGo), water-soluble protein (ProGo), calcium/collagen (CalGo and NT-II), and non-soluble protein (PetGo), all of which are produced in the Midsund plant. The firm sells its products to various segments of the human nutrition market, such as sports nutrition, supplements, and health foods, as well as to the market within nutrition for the pet and feed industry. Geographically, the company generates maximum revenue from Europe, followed by North America and Asia.
51GF Score
Get the complete analysis for HOFBF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOFBF has been successfully added to your 
